These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 6441496)
1. Metabolites of cardiac antiarrhythmic drugs: their clinical role. Kates RE Ann N Y Acad Sci; 1984; 432():75-89. PubMed ID: 6441496 [TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of the newer antiarrhythmic agents. Gillis AM; Kates RE Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721 [TBL] [Abstract][Full Text] [Related]
3. Importance of metabolites in antiarrhythmic therapy. Woosley RL; Roden DM Am J Cardiol; 1983 Sep; 52(6):3C-7C. PubMed ID: 6194679 [TBL] [Abstract][Full Text] [Related]
4. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. Woosley RL; Echt DS; Roden DM Am J Cardiol; 1986 Jan; 57(3):25B-33B. PubMed ID: 3080860 [TBL] [Abstract][Full Text] [Related]
5. Metabolites of antiarrhythmic drugs: are they clinically important? Kates RE Ration Drug Ther; 1986 May; 20(5):1-5. PubMed ID: 3097754 [No Abstract] [Full Text] [Related]
6. The clinical pharmacology of lidocaine congeners--review of encainide, flecainide, lorcainide and tocainide. McDevitt DG Eur Heart J; 1984 Sep; 5 Suppl B():63-6. PubMed ID: 6437818 [TBL] [Abstract][Full Text] [Related]
7. Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide. Pottage A Am J Cardiol; 1983 Sep; 52(6):24C-31C. PubMed ID: 6414279 [TBL] [Abstract][Full Text] [Related]
8. Reliability of antiarrhythmic drug plasma concentration monitoring. Follath F; Ganzinger U; Schuetz E Clin Pharmacokinet; 1983; 8(1):63-82. PubMed ID: 6404580 [TBL] [Abstract][Full Text] [Related]
9. New drugs in the management of ventricular arrhythmias. Sanna GP G Ital Cardiol; 1984 Oct; 14(10):788-97. PubMed ID: 6083894 [TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of antiarrhythmic drugs. Block PJ; Winkle RA Am J Cardiol; 1983 Sep; 52(6):14C-23C. PubMed ID: 6414278 [TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of old and new antiarrhythmic drugs. Siddoway LA; Roden DM; Woosley RL Cardiovasc Clin; 1985; 15(3):199-248. PubMed ID: 2870805 [TBL] [Abstract][Full Text] [Related]
12. Clinical importance of metabolites of antiarrhythmic drugs. Kates RE; Woosley RL; Harrison DC Am J Cardiol; 1984 Jan; 53(1):248-51. PubMed ID: 6419577 [No Abstract] [Full Text] [Related]
13. Clinical pharmacokinetics of antiarrhythmic drugs. Harrison DC; Meffin PJ; Winkle RA Prog Cardiovasc Dis; 1977; 20(3):217-42. PubMed ID: 335439 [No Abstract] [Full Text] [Related]
14. Antiarrhythmic drug therapy. Recent advances and current status. Somberg J Cardiology; 1985; 72(5-6):329-48. PubMed ID: 2866841 [TBL] [Abstract][Full Text] [Related]
15. Comparative antiarrhythmic actions of encainide and its major metabolites. Gomoll AW; Byrne JE; Mayol RF Arch Int Pharmacodyn Ther; 1986 Jun; 281(2):277-97. PubMed ID: 3092755 [TBL] [Abstract][Full Text] [Related]
17. Antiarrhythmic drug therapy for sustained ventricular tachycardia. Kienzle MG; Williams PD; Zygmont D; Doherty JU; Josephson ME Heart Lung; 1984 Nov; 13(6):614-22. PubMed ID: 6149202 [TBL] [Abstract][Full Text] [Related]
18. New antiarrhythmic drugs: their place in therapy. Keefe DL; Kates RE; Harrison DC Drugs; 1981 Nov; 22(5):363-400. PubMed ID: 6800757 [No Abstract] [Full Text] [Related]
19. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. Wang T; Roden DM; Wolfenden HT; Woosley RL; Wood AJ; Wilkinson GR J Pharmacol Exp Ther; 1984 Mar; 228(3):605-11. PubMed ID: 6423808 [TBL] [Abstract][Full Text] [Related]
20. Series on pharmacology in practice. 2. Antiarrhythmic drug therapy. Federman J; Vlietstra RE Mayo Clin Proc; 1979 Aug; 54(8):531-42. PubMed ID: 459565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]